Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02891642
Other study ID # Laboratory Medicine-001
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date September 2016
Est. completion date February 2021

Study information

Verified date February 2020
Source The First Affiliated Hospital with Nanjing Medical University
Contact Jian Xu, MD/ PhD
Phone +8602568135230
Email xu_jian79@163.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of the current study is to establish a Liquid biopsy method (positive enrichment by a novel immunomagnetic beads capture assay) for detection of malignant cell in serous effusions and to evaluate its sensitivity and specificity for clinical application.


Description:

A serous effusion is common event in metastatic carcinoma, but it also can be associated with other benign medical conditions. Current standard method for detecting malignancy is by cytological examination. However, cytological examination is often low sensitive, often due to the large amount of fluid with relatively sparse tumor cells present and the presence of many normal cells such as mesothelial cell. The investigators have developed a new method, malignant cell enrichment with immunomagnetic beads capture followed by Pap staining and NGS, to identify target malignant cells in body fluids.

McAb NJ001 is developed for malignant cell isolation with immunomagnetic beads capture technique. This is a prospective, multi-center, double-blind, statistically powered clinical trial that will enroll patients scheduled to undergo a procedure for removal of fluid from a serous effusion with or without clinical diagnosis of caner. The purpose of the current study is to compare the novel serous effusion detection assay using NJ001 coated immunomagnetic beads capture followed by Pap staining and NGS analysis with traditional cytologic evaluation.


Recruitment information / eligibility

Status Recruiting
Enrollment 1000
Est. completion date February 2021
Est. primary completion date February 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- Males or females >18 years of age;

- Have a serous effusion;

- Scheduled for a diagnostic and/or therapeutic procedure to remove serous fluid ( Puncture of serous cavity).

Exclusion Criteria:

- Females known to be pregnant;

Study Design


Intervention

Device:
Immunomagnetic Detection
Immunomagnetic separation will be assessed through analysis of the percentage of positive samples identified compared to cytological techniques.

Locations

Country Name City State
China The First Affiliated Hospital with Nanjing Medical University Nanjin Jiangsu
China The First Affiliated Hospital of Nanjing Medical University Nanjing Jiangsu

Sponsors (9)

Lead Sponsor Collaborator
The First Affiliated Hospital with Nanjing Medical University Anhui Provincial Hospital, Jiangsu Cancer Institute & Hospital, M.D. Anderson Cancer Center, Renmin Hospital of Wuhan University, Sir Run Run Shaw Hospital, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, University of California, Los Angeles, Xuanwu Hospital, Beijing

Country where clinical trial is conducted

China, 

References & Publications (1)

Pan S, Wang F, Huang P, Xu T, Zhang L, Xu J, Li Q, Xia W, Sun R, Huang L, Peng Y, Qin X, Shu Y, Hu Z, Shen H. The study on newly developed McAb NJ001 specific to non-small cell lung cancer and its biological characteristics. PLoS One. 2012;7(3):e33009. doi: 10.1371/journal.pone.0033009. Epub 2012 Mar 30. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants with Malignancies Assessed by the Liquid Biopsy with Immunomagnetic Beads Capture Technique (Cancer Cell Positive Enrichment) SP70 positive The samples will be analyzed within 18 months
See also
  Status Clinical Trial Phase
Completed NCT04159831 - A Study to Evaluate LTI-01 in Patients With Infected, Non-draining Pleural Effusions Phase 2
Completed NCT02232841 - Electrical Impedance Imaging of Patients on Mechanical Ventilation N/A
Completed NCT02045641 - Pleural and Pericardial Effusion Following Open Heart Surgery N/A
Completed NCT01948076 - Evaluation of a Pocket-Sized Ultrasound Device As an Aid to the Physical Examination N/A
Completed NCT01416519 - Physiotherapy Technique Decreases Respiratory Complications After Cardiac Operation N/A
Completed NCT01560078 - Efficacy Study of Thrice Weekly Directly Observed Treatment Short-Course Regimen in Tubercular Pleural Effusion N/A
Completed NCT04891705 - Point of Care Ultrasound Lung Artificial Intelligence (AI) Validation Data Collection Study
Recruiting NCT05759117 - Prospective Evaluation of Patients With Pleural Effusion
Recruiting NCT05910112 - Prospective Data Collection on Clinical, Radiological and Patient Reported Outcomes After Pleural Intervention
Completed NCT03896672 - Clinical Implementation of the Use of Positive Pressure in Chest Drainage N/A
Active, not recruiting NCT06075836 - AI Assisted Detection of Chest X-Rays
Recruiting NCT03728491 - Education and Training Competences in Thoracic Ultrasound N/A
Not yet recruiting NCT03260088 - Evaluation Of Pleural Effusion At Assiut University Hospital N/A
Completed NCT03535883 - The Safety of Thoracentesis, Tunneled Pleural Catheter, and Chest Tubes in Patients Taking Novel Oral Anti-Coagulants
Completed NCT03296280 - Evaluation of Implementation of a National Point-of-Care Ultrasound Training Program
Completed NCT03661801 - Novel Pleural Fluid, Biopsy and Serum Biomarkers for the Investigation of Pleural Effusions
Completed NCT01778270 - Not Invasive Monitoring of Pleural Drainage N/A
Terminated NCT00402896 - Malignant Pleural Effusion With ZD6474 Phase 2
Recruiting NCT00103766 - Alteplase for Treatment of Empyema and Complicated Parapneumonic Effusion N/A
Completed NCT03327688 - Point-of-care Ultrasound in Finland N/A